Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17207271 | 0.81 | — | — | |
| SCHEMBL2841006 | 0.80 | ALDH1A1 (0.53) | TSHRHSD17B10ALDH1A1LMNAEPHX2 | |
| SCHEMBL4300352 | 0.80 | ALDH1A1 (0.53) | TSHRHSD17B10ALDH1A1LMNAEPHX2 | |
| SCHEMBL11335823 | 0.80 | TSHR (0.46) | CYP4F2CYP4A11TSHRHSD17B10MGAM | |
| SCHEMBL821076 | 0.77 | TSHR (0.53) | CYP4F2CYP4A11TSHRHSD17B10MGAM | |
| SCHEMBL869082 | 0.77 | TSHR (0.53) | CYP4F2CYP4A11TSHRHSD17B10MGAM | |
| SCHEMBL869080 | 0.77 | TSHR (0.53) | CYP4F2CYP4A11TSHRHSD17B10MGAM | |
| SCHEMBL13670835 | 0.76 | ALOX15 (0.40) | CYP4F2CYP4A11TSHRHSD17B10MGAM | |
| SCHEMBL13670844 | 0.74 | CYP4F2 (0.34) | CYP4F2CYP4A11TSHRHSD17B10MGAM | |
| SCHEMBL9449027 | 0.74 | TSHR (0.52) | CYP4F2CYP4A11TSHRHSD17B10MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120742-B2 | Methods of making organic compounds by metathesis | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20090264672-A1 | METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264672-A1 | METHODS OF MAKING ORGANIC COMPOUNDS BY METATHESIS | COASY, FASN, HAO2 | CYP4F2 365/4885CYP4A11 351/4885TSHR 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.